How similar is your antibody to clinical-stage therapeutics?
The earlier error has now been fixed and jobs should be running normally. Thanks for your understanding, and sorry for the inconvenience. --Claire
For a full description of the profiler, or if you use this software, please refer to: Raybould MIJ, et al. Five Computational Developability Guidelines for Therapeutic Antibody Profiling. PNAS. (2019)
Please cite our paper "Five Computational Developability Guidelines for Therapeutic Antibody Profiling" if making use of these datasets.
|Property||Amber Region (16th June 2019)||Red Region (16th June 2019)|
|Total CDR Length (L)||39 ≤ L ≤ 42||L < 39|
|55 ≤ L ≤ 60||L > 60|
|Patches of Surface Hydrophobicity (PSH)||88.2933 ≤ PSH ≤ 100.788||PSH < 88.2933|
|158.470 ≤ PSH ≤ 179.175||PSH > 179.175|
|Patches of Positive Charge (PPC)||1.2336 ≤ PPC ≤ 3.7545||PPC > 3.7545|
|Patches of Negative Charge (PNC)||1.8333 ≤ PNC ≤ 3.4688||PNC > 3.4688|
|Structural Fv Charge Symmetry Parameter (SFvCSP)||-19.50 ≤ SFvCSP ≤ -6.016||SFvCSP < -19.50|
Please visit Thera-SAbDab to access all of our CST sequence data.